Zaviceftabis a combination antibiotic for Gram-negative bacterial infections requiring hospitalisation
The WHO characterises antimicrobial resistance as one of the biggest threats to global health
Pfizer's Zavicefta is now available in the UK and Germany. Zavicefta is a combination antibiotic for the treatment of patients with certain confirmed or suspected Gram-negative bacterial infections requiring hospitalisation.
Pfizer expects to launch Zavicefta in additional markets outside the US throughout 2017 and 2018.
Zavicefta was developed in response to the urgent need for new antibiotics for difficult-to-treat Gram-negative bacteria, many of which have become increasingly resistant to currently available antibiotics.
Zavicefta is indicated for the treatment of adults with complicated intra-abdominal infection (cIAI), complicated urinary tract infection (cUTI) and Hospital-Acquired Pneumonia, including Ventilator Associated Pneumonia.
It is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adult patients with limited treatment options.
Zavicefta addresses Pseudomonas Aeruginosa and Enterobacteriaceae, two of three “critical” pathogens recently identified by the World Health Organisation.
In many markets, existing treatments do not consistently address these resistant pathogens adequately.
“Multidrug-resistant infections are an increasing global threat,” said Matteo Bassetti, Chief of the Infectious Diseases Clinic at University of Udine in Italy.
“The availability of Zavicefta is a major step forward for physicians faced with the challenge of treating patients with known or suspected MDR infections.”